Eli Lilly said preliminary data from a late-stage study showed its weight-loss drug significantly reduced the risk of progression to type 2 diabetes among adults with prediabetes and obesity or overweight.
Eli Lilly said preliminary data from a late-stage study showed its weight-loss drug significantly reduced the risk of progression to type 2 diabetes among adults with prediabetes and obesity or overweight.